Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte- reconstituted mice

Journal of Infectious Diseases

Volumn 206, Issue 10, 2012, Pages 1577-1588

  Roy, Upal ^a   McMillan, Joellyn ^a   Alnouti, Yazen ^d   Gautum, Nagsen ^d   Smith, Nathan ^a   Balkundi, Shantanu ^a   Dash, Prasanta ^a   Gorantla, Santhi ^a   Martinez Skinner, Andrea ^a   Meza, Jane ^c   Kanmogne, Georgette ^a   Swindells, Susan ^b   Cohen, Samuel M ^b   Lee Mosley, R ^a   Poluektova, Larisa ^a   Gendelman, Howard E ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

^b Department of Otolaryngology Head and Neck Surgery   (United States)

^c and Medical Genetics   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; EFAVIRENZ; LONG ACTING NANOFORMULATED ANTIRETROVIRUS AGENT; MACROGOL 2000; POLOXAMER; RITONAVIR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF DETECTION; MALE; MOUSE; NANOPHARMACEUTICS; NONHUMAN; PERIPHERAL LYMPHOCYTE; PHARMACODYNAMICS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; DOSAGE FORMS; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV INFECTIONS; HUMANS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; LYMPHOCYTES; MALE; MICE; MICE, KNOCKOUT; MICE, SCID; NANOSTRUCTURES; T-LYMPHOCYTE SUBSETS;

EID: 84867696503     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis395     Document Type: Article

References (42)

1. Broder MS, Chang EY, Bentley TG, Juday T, Uy J. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naive human immunodeficiency virus-infected patients in the United States. J Med Econ 2011; 14:167-78.
2. Swindells S, Flexner C, Fletcher CV, Jacobson JM. The critical need for alternative antiretroviral formulations, and obstacles to their development. J Infect Dis 2011; 204:669-74.
3. Chesney MA, Ickovics J, Hecht FM, Sikipa G, Rabkin J. Adherence: a necessity for successful HIV combination therapy. AIDS 1999; 13 (suppl A):S271-8.
4. Braithwaite RS, Shechter S, Roberts MS, et al. Explaining variability in the relationship between antiretroviral adherence and HIV mutation accumulation. J Antimicrob Chemother 2006; 58:1036-43.
5. Batrakova EV, Li S, Brynskikh AM, et al. Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers. J Control Release 2010; 143:290-301.
6. Bressani RF, Nowacek AS, Singh S, et al. Pharmacotoxicology of monocyte-macrophage nanoformulated antiretroviral drug uptake and carriage. Nanotoxicology 2011; 5:592-605.
7. Nowacek AS, McMillan J, Miller R, Anderson A, Rabinow B, Gendelman HE. Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics. J Neuroimmune Pharmacol 2010; 5:592-601.
8. Batrakova EV, Gendelman HE, Kabanov AV. Cell-mediated drug delivery. Expert Opin Drug Deliv 2011; 8:415-33.
9. Kadiu I, Nowacek A, McMillan J, Gendelman HE. Macrophage endocytic trafficking of antiretroviral nanoparticles. Nanomedicine (Lond) 2011; 6:975-94.
10. Nowacek AS, Balkundi S, McMillan J, et al. Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J Control Release 2011; 150:204-11.
11. Balkundi S, Nowacek AS, Veerhubotla RS, et al. Comparative manufacture and cell-based delivery of antiretroviral nanoformulations. Int J Nanomedicine 2011; 6:3393-3404.
12. Nowacek AS, Miller RL, McMillan J, et al. NanoART synthesis, characterization, uptake, release and toxicology for human monocytemacrophage drug delivery. Nanomedicine (Lond) 2009; 4:903-17.
13. Nowacek A, Gendelman HE. NanoART, neuroAIDS and CNS drug delivery. Nanomedicine (Lond) 2009; 4:557-74.
14. Dou H, Grotepas CB, McMillan JM, et al. Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J Immunol 2009; 183:661-9.
15. Dou H, Destache CJ, Morehead JR, et al. Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood 2006; 108:2827-35.
16. Robinson BS, Riccardi KA, Gong YF, et al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother 2000; 44:2093-9.
17. Berges BK, Rowan MR. The utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment. Retrovirology 2011; 8:65.
18. Balkundi S, Nowacek AS, Roy U, Martinez-Skinner A, McMillan J, Gendelman HE. Methods development for blood borne macrophage carriage of nanoformulated antiretroviral drugs. J Vis Exp 2010; (46) pii:2460.
19. Huang J, Gautam N, Bathena SP, et al. UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879:2332-8.
20. Gendelman HE, Orenstein JM, Martin MA, et al. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med 1988; 167:1428-41.
21. Poluektova LY, Munn DH, Persidsky Y, Gendelman HE. Generation of cytotoxic T cells against virus-infected human brain macrophages in a murine model of HIV-1 encephalitis. J Immunol 2002; 168:3941-9.
22. Gendelman HE, Genis P, Jett M, Zhai QH, Nottet HS. An experimental model system for HIV-1-induced brain injury. Adv Neuroimmunol 1994; 4:189-93.
23. Stoddart CA, Bales CA, Bare JC, et al. Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals. PLoS One 2007; 2:e655.
24. Poluektova L, Gorantla S, Faraci J, Birusingh K, Dou H, Gendelman HE. Neuroregulatory events follow adaptive immune-mediated elimination of HIV-1-infected macrophages: studies in a murine model of viral encephalitis. J Immunol 2004; 172:7610-7.
25. Gorantla S, Makarov E, Finke-Dwyer J, et al. CD8+ cell depletion accelerates HIV-1 immunopathology in humanized mice. J Immunol 2010; 184:7082-91.
26. Ohbo K, Suda T, Hashiyama M, et al. Modulation of hematopoiesis in mice with a truncated mutant of the interleukin-2 receptor gamma chain. Blood 1996; 87:956-67.
27. Pino S, Brehm MA, Covassin-Barberis L, et al. Development of novel major histocompatibility complex class I and class II-deficient NODSCID IL2R gamma chain knockout mice for modeling human xenogeneic graft-versus-host disease. Methods Mol Biol 2010; 602:105-17.
28. King MA, Covassin L, Brehm MA, et al. Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. Clin Exp Immunol 2009; 157:104-18.
29. Best BM, Letendre SL, Brigid E, et al. Low atazanavir concentrations in cerebrospinal fluid. AIDS 2009; 23:83-7.
30. AIDSinfo, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adult andadolescentgl.pdf. Accessed 2 November 2011.
31. Lopez-Cortes LF, Ruiz-Valderas R, Marin-Niebla A, Pascual-Carrasco R, Rodriguez-Diez M, Lucero-Munoz MJ. Therapeutic drug monitoring of efavirenz: trough levels cannot be estimated on the basis of earlier plasma determinations. J Acquir Immune Defic Syndr 2005; 39:551-6.
32. Mosier DE. Distinct rate and patterns of human CD4+ T-cell depletion in hu-PBL-SCID mice infected with different isolates of the human immunodeficiency virus. J Clin Immunol 1995; 15: 130S-3S.
33. Mosier DE, Gulizia RJ, MacIsaac PD, Torbett BE, Levy JA. Rapid loss of CD4+ T cells in human-PBL-SCID mice by noncytopathic HIV isolates. Science 1993; 260:689-92.
34. Gorantla S, Santos K, Meyer V, et al. Human dendritic cells transduced with herpes simplex virus amplicons encoding human immunodeficiency virus type 1 (HIV-1) gp120 elicit adaptive immune responses from human cells engrafted into NOD/SCID mice and confer partial protection against HIV-1 challenge. J Virol 2005; 79:2124-32.
35. Gorantla S, Sneller H, Walters L, et al. Human immunodeficiency virus type 1 pathobiology studied in humanized BALB/c-Rag2-/-gammac-/-mice. J Virol 2007; 81:2700-12.
36. Wood E, Hogg RS, Yip B, et al. Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use. AIDS 2005; 19:1189-95.
37. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368:505-10.
38. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resourcelimited settings: systemic review and meta-analysis. PLoS One 2009; 4: e5790.
39. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, 2006 revision. http://www.who.int/hiv/pub/guidelines/artadult guidelines.pdf. Accessed 17 November 2011.
40. Huff-Rousselle M, Simooya O, Kabwe V, et al. Pharmacovigilance and new essential drugs in Africa: Zambia draws lessons from its own experiences and beyond. Glob Public Health 2007; 2:184-203.
41. Kabanov AV, Gendelman HE. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci 2007; 32: 1054-82.
42. Gendelman HE, Kabanov A, Linder J. The promise and perils of CNS drug delivery: a video debate. J Neuroimmune Pharmacol 2008; 3:58.